GLP-1 Drugs: Weight Loss and Chronic Disease Treatment
- Recent research suggests that semaglutide, a medication used for weight loss, may also reduce the risk of cardiovascular events, potentially shifting how overweight and obesity are viewed in...
- Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist initially approved by the U.S.
- In June 2021, the FDA approved Wegovy (semaglutide) 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as...
“`html
Recent research suggests that semaglutide, a medication used for weight loss, may also reduce the risk of cardiovascular events, potentially shifting how overweight and obesity are viewed in healthcare and impacting insurance coverage.
Semaglutide (Wegovy) and Weight Management
Table of Contents
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist initially approved by the U.S. Food and Drug Governance (FDA) for treating type 2 diabetes, and later for chronic weight management. It works by mimicking the effects of GLP-1, a natural hormone that regulates appetite and blood sugar levels.
In June 2021, the FDA approved Wegovy (semaglutide) 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
Evidence: The FDA approval of Wegovy was based on the SELECT trial, a randomized, double-blind, placebo-controlled trial involving nearly 18,000 adults with obesity and established cardiovascular disease.
Cardiovascular Benefits of Semaglutide
Studies indicate that semaglutide can reduce the occurrence of major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death. This finding is notable because obesity is a well-established risk factor for cardiovascular disease.
The SELECT trial, published in the New England Journal of Medicine in August 2023, demonstrated a 15% reduction in the risk of MACE in adults with obesity and established cardiovascular disease who were treated with semaglutide 2.4 mg compared to those who received a placebo.
Example: The SELECT trial involved 17,642 adults across 30 countries, and the median follow-up period was 3.4 years. The primary outcome, MACE, occured in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio 0.85; 95% confidence interval 0.77 to 0.94; P=0.0021).
Oral Semaglutide and Cardiovascular Risk
Semaglutide is available in both injectable and oral formulations.Research suggests that the cardiovascular benefits of semaglutide extend to the oral form of the medication.
A study published in Diabetes, Obesity and Metabolism in 2023 showed that oral semaglutide also demonstrated improvements in cardiovascular risk factors, including reductions in blood pressure, cholesterol levels, and inflammatory markers. While the MACE reduction hasn’t been definitively established with oral semaglutide to the same degree as the injectable form, the positive impact on risk factors is promising.
Detail: The oral formulation of semaglutide (Rybelsus) requires specific administration instructions to maximize absorption, including taking it on an empty stomach first thing in the morning and avoiding food or other medications for at least 30 minutes.
Insurance Coverage and access
The potential for expanded insurance coverage for semaglutide and similar medications is a key discussion point, given the demonstrated cardiovascular benefits. Currently, coverage varies widely depending on the insurance plan and the individual’s medical history.
Medicare coverage for obesity medications is limited, but the recent findings regarding cardiovascular benefits may prompt a reevaluation of coverage policies. The Centers for Medicare & Medicaid Services (CMS) regularly updates its National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) based on new evidence.
Status as of January 11, 2026: As of January 11,